Qiagen N.V.. (7/26/23). "Press Release: Bio-Rad and Qiagen Announce Patent Settlement and Cross-licensing Agreement". Venlo.

	Organisation	Qiagen N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA)
	Group	Qiagen (Group)
	Organisation 2	Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb)
	Group	Bio-Rad (Group)
	Product	digital PCR technology (dPCR)
	Product 2	IP services
	Person	Gilardi, John (Qiagen 201211 Investor Relations)

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with over 8,000 employees and $2.8 billion in revenues in 2022. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). In 2022, QIAGEN had net sales of more than $2.1 billion and over 6,200 employees. Further information can be found at http://www.qiagen.com.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.

QIAGEN is a trademark of QIAGEN N.V. in certain jurisdictions.

Edward Chung
Bio-Rad Laboratories, Inc.
510-741-6104
ir@bio-rad.com

Anna Gralinska
Bio-Rad Laboratories, Inc.
510-741-6643
cc@bio-rad.com

Press Contact

Daniela Eltrop
Associate Director Public Relations
Germany: +49 2103 29 11676
Mobile: +49 152 01811676
daniela.eltrop@qiagen.com

Lisa Mannagottera
Associate Manager Public Relations
Germany: +49 2103 29 14181
Mobile: +49 152 01811381
lisa.mannagottera@qiagen.com

Dr. Thomas Theuringer
Senior Director Corporate Communications & Head Of External
Germany: +49 2103 29 11826
U.S.: +1 240 686 7425
The Netherlands: +31 773 55 66 66
thomas.theuringer@qiagen.com

IR Contacts

Phoebe Loh
Senior Director Investor Relations
+49 2103 29 11457
phoebe.loh@qiagen.com

Alexandra Koenig
Investor Relations Coordinator
+49 2103 29 11709
alexandra.koenig@qiagen.com

John Gilardi
Vice President
Head of Corporate Communications and Investor Relations
Germany +49 2103 29 11711
U.S. +1 240 686 2222
The Netherlands +31 773 55 66 66
john.gilardi@qiagen.com

Record changed: 2024-01-20